TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23116213

Group type: COMPARATOR
Intervention: NHS Health Check service only
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: NHS Health Check service plus additional lifestyle support
Number of subjects: 601
Study: 20157024

Group type: EXPERIMENTAL
Intervention: 3D prosthetic mimics of lesions and eruptions
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2D images
Number of subjects: 90
Study: 18728372

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 198

Group type: COMPARATOR
Intervention: No aspirin treatment (Control)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (before and after)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aspirin-resistant group
Number of subjects: 198
Study: 16296923

Group type: EXPERIMENTAL
Intervention: Direct Vision (DV) training
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dynamic digital gas‐discharge visualization (GDV) bioelectrography
Number of subjects: 7
Study: 11889662

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (Acupuncture and Sham Acupuncture)
Number of subjects: 18
Study: 9697788

Group type: EXPERIMENTAL
Intervention: PSA corrected for total prostate volume (PSA-D)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: PSA corrected for transition zone volume (PSA-T)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: PSA alone
Number of subjects: 1202
Study: 8563871

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg prednisolone daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg prednisolone daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: megadose pulsed steroid therapy (500 or 1000 mg hydrocortisone-21-sodium succinate or methylprednisolone intravenously once a day)
Number of subjects: 24
Study: 2514981

Group type: EXPERIMENTAL
Intervention: High-dose L-deprenyl (up to 40 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conventional doses of deprenyl (10 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 335093

Group type: EXPERIMENTAL
Intervention: High-dose terbutaline sulfate (1.5 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-dose terbutaline sulfate (0.75 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.3 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31608822

Group type: EXPERIMENTAL
Intervention: Information about childhood trauma history (interpersonal)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Information about childhood trauma history (non-interpersonal)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Information about childhood trauma history
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Contextual information about pregnancy status (pregnant)
Number of subjects: 461
Study: 31655410

Group type: EXPERIMENTAL
Intervention: rBoNT-E (0.04-3.6 ng)
Number of subjects: 52

Group type: COMPARATOR
Intervention: abobotulinumtoxinA (20, 40, or 70 U)
Number of subjects: 52
Study: 27427555

Group type: EXPERIMENTAL
Intervention: Low-energy shock-wave therapy (LESWT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stem cell (BMSC) transplantation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of LESWT and BMSC transplantation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Diabetic group)
Number of subjects: 42
Study: 26011919

Group type: COMPARATOR
Intervention: Dieting (reduced daily intake by 500 kilocalories)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise (moderate-intensity aerobic and resistance exercise, 200-300 min/week)
Number of subjects: 80
Study: 23065432

Group type: EXPERIMENTAL
Intervention: Extended daily hemodialysis (EHD)
Number of subjects: 407

Group type: COMPARATOR
Intervention: High volume peritoneal dialysis (HVPD)
Number of subjects: 407
Study: 21777452

Group type: EXPERIMENTAL
Intervention: Healthy Toddlers intervention (eight in-home lessons and four reinforcement telephone contacts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Toddlers intervention
Number of subjects: 0
Study: 18280767

Group type: EXPERIMENTAL
Intervention: Bilateral manipulation of talocrural joints (n=32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 62
Study: 16624773

Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg before operation and 80 microg/h for 48 h after operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural injection of normal saline before operation and 0.15% ropivacaine 2.0 ml/h for 48 h after operation
Number of subjects: 40
Study: 13680104

Group type: EXPERIMENTAL
Intervention: Transfix and periosteal flap
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transfix and resorbable screw
Number of subjects: 41
Study: 11411461

Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine (100 mg po)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 9236426

Group type: EXPERIMENTAL
Intervention: Early angiography and revascularization (angioplasty or bypass surgery) within 24 hours of shock onset
Number of subjects: 2200

Group type: COMPARATOR
Intervention: No early angiography and revascularization
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Aggressive strategy of early angiography
Number of subjects: 2200
Study: 7962283

Group type: EXPERIMENTAL
Intervention: alpha-methyl-para-tyrosine (AMPT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: promethazine (control)
Number of subjects: 7
Study: 2890525

Group type: EXPERIMENTAL
Intervention: Fentanyl analgesia
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Alfentanil analgesia
Number of subjects: 1600
Study: 30504404

Group type: EXPERIMENTAL
Intervention: Surgery plus neoadjuvant radiochemotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 52
Study: 26866979

Group type: EXPERIMENTAL
Intervention: 7-day dolutegravir functional monotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: 7-day placebo
Number of subjects: 28
Study: 24739083

Group type: EXPERIMENTAL
Intervention: Ice skating (8 sessions during education lessons)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal physical education (control group)
Number of subjects: 30
Study: 23357764

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (1,500 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20447934

Group type: EXPERIMENTAL
Intervention: Exposed to smoking (1 cigarette)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Unexposed control (time-lapse equivalent)
Number of subjects: 41
Study: 18166815

Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Repaglinide (2 mg thrice daily)
Number of subjects: 96
Study: 15781543

Group type: EXPERIMENTAL
Intervention: 10 mL of 15% magnesium sulfate (12.4 mmol) plus 3 mg/kg lidocaine 0.5% diluted with saline to a total of 40 mL in group M
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 mL of saline plus 3 mg/kg lidocaine 0.5% diluted with saline to a total of 40 mL in group C
Number of subjects: 30
Study: 14632754

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (3.2 mg subcutaneous injections twice weekly for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no injections for 12 weeks)
Number of subjects: 20
Study: 10573277

Group type: EXPERIMENTAL
Intervention: ILIAD (version 4.2)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Quick Medical Reference (QMR; version 3.7.1)
Number of subjects: 216
Study: 8721025

Group type: EXPERIMENTAL
Intervention: rHuEPO at a dose of 150 IU/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rHuEPO at a dose of 250 IU/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rHuEPO at a dose of 400 IU/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Initial EPO levels < 100 IU/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Initial EPO levels > 100 IU/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 15
Study: 1760823

Group type: EXPERIMENTAL
Intervention: Slow-release isosorbide-5-mononitrate (IS-5-MN), 25 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupranolol, 50 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of IS-5-MN and bupranolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drugs (IS-5-MN and bupranolol)
Number of subjects: 30
Study: 6123810

Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg or 30 mg per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31784436

Group type: EXPERIMENTAL
Intervention: L2B Plus (Learning to BREATHE plus ecological momentary intervention)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Active health and wellness control condition
Number of subjects: 38
Study: 30284172

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention consisting of a personalized decision support tool, educational program, performance measure, and audit and feedback system.
Number of subjects: 3787

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention ended.
Number of subjects: 3787
Study: 26931572

Group type: EXPERIMENTAL
Intervention: Violence prevention intervention (community conversations and planning focused on enhancing the value of girls in the community)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Educational intervention (cash transfer to the household conditioned on school enrollment and attendance)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Health intervention (culturally relevant, age-appropriate sexual and reproductive health education delivered in a group setting once a week for 2 years)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Wealth creation intervention (savings and financial education, as well as start-up savings)
Number of subjects: 6000
Study: 24118351

Group type: EXPERIMENTAL
Intervention: Dual-wavelength laser system treatment (pulsed dye laser and Nd:YAG)
Number of subjects: 12
Study: 22364209

Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 343
Study: 19434815

Group type: EXPERIMENTAL
Intervention: Levamisole plus colchicine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 64
Study: 17880351

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) with 2 sessions
Number of subjects: 539

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 539
Study: 15447921

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Higher dairy product consumption
Number of subjects: 745

Group type: COMPARATOR
Intervention: Calcium intake
Number of subjects: 745
Study: 11515644

Group type: EXPERIMENTAL
Intervention: Glass-ionomer sealant (Fuji III)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Resin-based sealant (Delton)
Number of subjects: 179
Study: 9609894

Group type: EXPERIMENTAL
Intervention: Liquid meal (5 mg per kilogram of body weight)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No meal (control group)
Number of subjects: 14
Study: 7824868

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 72
Study: 2970080

Group type: EXPERIMENTAL
Intervention: Y connection system (Group IA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional technique (Group IB)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Y connection system (Group II)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional technique (Group III)
Number of subjects: 126
Study: 1958910

Group type: EXPERIMENTAL
Intervention: Pay group (user fees)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No pay group (no user fees)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both groups (pay and no pay)
Number of subjects: 59
Study: 340136

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 200 mg atenolol
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 30187641

Group type: EXPERIMENTAL
Intervention: ILM peeling of 2DD
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ILM peeling of 4DD
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: MHCI ≤0.5
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: MHCI >0.5
Number of subjects: 121
Study: 28611007

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Achieving 5% weight loss
Number of subjects: 450
Study: 26163302

Group type: EXPERIMENTAL
Intervention: Mindfulness bibliotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 90
Study: 23543129

Group type: COMPARATOR
Intervention: NYHA class III
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: NYHA class IV
Number of subjects: 405
Study: 21376161

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17Pc), 250 mg weekly injections starting at 16-24 weeks until 34 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17Pc)
Number of subjects: 240
Study: 19236894

Group type: EXPERIMENTAL
Intervention: Play equipment provided
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Markings painted on the playground
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Play equipment provided and markings painted
Number of subjects: 583

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 583
Study: 17429083

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously once daily for 13 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 15976592

Group type: EXPERIMENTAL
Intervention: Rigid lens (Z-alpha, Menicon Co. Ltd.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Soft lens (Focus Night & Day, Ciba Vision)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both lens types
Number of subjects: 100
Study: 11689580

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg subcutaneously three times per week, doubled after 4 weeks for non-responders
Number of subjects: 401
Study: 9394855

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg q.i.d.
Number of subjects: 0
Study: 7934116

Group type: EXPERIMENTAL
Intervention: Bicaval anastomoses
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atrial anastomoses
Number of subjects: 18
Study: 3354875

Group type: COMPARATOR
Intervention: Aerosolized lidocaine and IV saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerosolized saline and IV lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine and IV lidocaine
Number of subjects: 40
Study: 30313028

Group type: EXPERIMENTAL
Intervention: LED therapy with phototherapy sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Orientation regarding breast care and adequate breastfeeding techniques (Control)
Number of subjects: 100
Study: 29175809

Group type: EXPERIMENTAL
Intervention: Agoraphobia Free mobile app
Number of subjects: 170

Group type: COMPARATOR
Intervention: Stress Free mobile app
Number of subjects: 170
Study: 26288120

Group type: EXPERIMENTAL
Intervention: High-speed gait training with HAL (20min/session, once a week for 8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 18
Study: 23704845

Group type: EXPERIMENTAL
Intervention: Culturally adapted dietary approach and exercise program, delivered through 24 group sessions, with daily food intake and physical activity recording.
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care (referral to a dietitian).
Number of subjects: 223
Study: 22120031

Group type: EXPERIMENTAL
Intervention: Task-oriented circuit class training with motor imagery (TOCCT with MI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard training program based on Bobath's neurodevelopmental technique
Number of subjects: 30
Study: 19909550

Group type: EXPERIMENTAL
Intervention: Intensified follow up
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Postoperative cancer relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Locoregional relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Distant relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both locoregional and distant relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stage IIIA relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stage IIB relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stage IIA relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stage IB relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mean disease free interval
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mean local relapse free interval
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mean distant relapse free interval
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Relapse within first 12 months
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: N stage and cancer relapse
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Significant factors for survival
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Specific oncological treatment of relapse
Number of subjects: 88
Study: 16780811

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/day) added to clozapine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus clozapine
Number of subjects: 20
Study: 16281460

Group type: EXPERIMENTAL
Intervention: Centrally-based coordinators for data collection
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Recruitment strategies for neuropsychological data
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Loss to follow-up
Number of subjects: 550
Study: 11121460

Group type: EXPERIMENTAL
Intervention: Social-influences, grade 3-12 intervention
Number of subjects: 8388

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 8388
Study: 8777117

Group type: EXPERIMENTAL
Intervention: i.v. diamorphine infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: s.c. diamorphine infusions
Number of subjects: 0
Study: 1705333

Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract pacing
Number of subjects: 33

Group type: COMPARATOR
Intervention: Right ventricular apex pacing
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both pacing sites
Number of subjects: 33
Study: 6150408

Group type: EXPERIMENTAL
Intervention: Azulfidine prophylaxis
Number of subjects: 177

Group type: COMPARATOR
Intervention: Radical operation
Number of subjects: 177

Group type: COMPARATOR
Intervention: More restricted operation
Number of subjects: 177

Group type: COMPARATOR
Intervention: No Azulfidine prophylaxis
Number of subjects: 177
Study: 30264048

Group type: EXPERIMENTAL
Intervention: Manual enhancement of occlusal morphology (MEOM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no MEOM)
Number of subjects: 80
Study: 27022636

Group type: EXPERIMENTAL
Intervention: Definitive screw‐retained metal‐ceramic prosthesis in occlusion within 1 week after placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non‐occluding provisional acrylic reinforced prosthesis within 24 h after implant placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non‐occluding provisional acrylic reinforced prosthesis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Definitive screw‐retained metal‐ceramic prosthesis in occlusion
Number of subjects: 50
Study: 25565584

Group type: EXPERIMENTAL
Intervention: Mindfulness in Action (MIA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pain management psychoeducation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 23426385

Group type: EXPERIMENTAL
Intervention: tranexamic acid (10‐mg/kg‐1 bolus and 10‐mg/kg‐1/h‐1 maintenance dose)
Number of subjects: 552

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 552
Study: 20573483

Group type: EXPERIMENTAL
Intervention: Previous trial(s) used for sample size calculations
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Meta-analyses cited in report discussion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Retrospective sample size calculations
Number of subjects: 27
Study: 18649051

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD+CRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICDs alone
Number of subjects: 0
Study: 15995568

Group type: EXPERIMENTAL
Intervention: Metotrexate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 24
Study: 12502673

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg o.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16
Study: 10552325

Group type: EXPERIMENTAL
Intervention: Side-shift therapy (mean treatment duration 2.2 years)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Brace treatment (historical cohort, mean brace treatment 3.0 years)
Number of subjects: 44
Study: 8699850

Group type: EXPERIMENTAL
Intervention: Neutrophil count measured from radial artery (RA) and coronary sinus (CS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Elastase concentrations measured from RA and CS
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lactoferrin concentrations measured from RA and CS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Neutrophil count comparison between CS and RA
Number of subjects: 19
Study: 534861

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0